区分肥胖与胰岛素抵抗对射血分数保留心力衰竭的影响
本研究基于PVDOMICS项目中276例HFpEF患者,分析肥胖与胰岛素抵抗对左心异常各自的贡献。结果显示肥胖(而非胰岛素抵抗)与双心室扩大、运动能力下降、生活质量差及静息和运动肺毛细血管楔压升高独立相关,并在独立队列(n=254)中重复验证。提示糖尿病主要是肥胖的标志,对心衰严重程度直接影响较小。
要点
- HFpEF患者中肥胖普遍存在,即使BMI<30 kg/m2者也有相当比例存在脂肪过多。
- 胰岛素抵抗与左心重构和肺毛细血管楔压无独立关联,肥胖则独立相关。
- 肥胖对静息和运动肺毛细血管楔压的关联在校正HOMA-IR后仍显著。
核心结论
- 肥胖而非胰岛素抵抗与HFpEF患者左心重构、血流动力学及功能受损独立相关。
- 糖尿病在HFpEF中主要是肥胖的标志,对心衰严重程度直接影响较小。
研究设计与样本
- 基于PVDOMICS研究(NCT02980887)中276例HFpEF患者,测量肥胖指标和胰岛素抵抗指标,比较静息和运动肺毛细血管楔压。
- 在独立HFpEF队列(n=254)中重复验证主要发现。
主要发现
- 276例HFpEF中246例(89%)腰高比增高,166例(60%)BMI≥30 kg/m2,其中114例(69%)有胰岛素抵抗,75例(45%)有糖尿病。
- 110例(40%)BMI<30 kg/m2的HFpEF中,44例(40%)有胰岛素抵抗,27例(25%)有糖尿病(均P<0.0001 vs 肥胖表型)。
- 肥胖(无论胰岛素抵抗状态)与双心室扩大、运动能力更差、生活质量更差及静息和运动肺毛细血管楔压更高相关(均P<0.01)。
- 肥胖与静息和动态肺毛细血管楔压反应升高相关(+4.4 mm Hg;95%CI:+2.5至+6.4 mm Hg;P<0.0001),校正HOMA-IR后仍显著(+4.7 mm Hg;95%CI:+2.7至+6.7 mm Hg;P<0.0001)。
- 脂肪量、BMI和腰围与静息和运动肺毛细血管楔压升高相关(均P<0.0009),但HOMA-IR无关联(+0.01 mm Hg;95%CI:-0.13至+0.16 mm Hg;P=0.84)。
关键数值与推荐
- 肥胖定义为BMI≥30 kg/m2;胰岛素抵抗定义为HOMA-IR≥2.6。
- 独立队列中BMI仍与静息和运动肺毛细血管楔压独立相关(每kg/m2 +0.19 mm Hg;95%CI:+0.11至+0.27 mm Hg;P<0.0001),糖尿病则无关联。
临床怎么用
- 对HFpEF患者应关注肥胖而非仅糖尿病状态,即使BMI<30 kg/m2也需评估脂肪过多。
- 需进一步研究BMI<30 kg/m2但脂肪过多的HFpEF患者的心脏代谢治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Obesity, insulin resistance (IR), and diabetes are common in heart failure with preserved ejection fraction (HFpEF) and are associated with worsening heart failure, but their independent contributions remain unknown. OBJECTIVES: In this study, we sought to determine the contribution of diabetes vs obesity to left heart abnormalities in HFpEF METHODS: Indices of adiposity (body mass index [BMI], bioimpedance fat mass, waist circumference) and IR (homeostasis-model assessment [HOMA]) were measured among PVDOMICS study participants with HFpEF. Rest and exercise pulmonary capillary wedge pressure (PCWP) responses were compared, stratified by obesity (BMI ≥30 kg/m2), IR status (HOMA-IR ≥2.6), and diabetes diagnosis. Findings were also tested in an independent HFpEF cohort. RESULTS: Of 276 patients with HFpEF, 246 (89%) had increased waist/height ratio, and 166 (60%) had BMI ≥30 kg/m2, with 114 (69%) of the latter having IR and 75 (45%) having diabetes. Of 110 (40%) with HFpEF and BMI <30 kg/m2, 44 (40%) had IR and 27 (25%) had diabetes (both P < 0.0001 vs obesity phenotype). The presence of IR was not associated with worse left heart remodeling or PCWP. In contrast, obesity (regardless of IR status) was associated with greater biventricular enlargement, worse exercise performance, poorer quality of life, and higher rest and exercise PCWP (P < 0.01 for all). Obesity was associated with higher rest and dynamic PCWP responses (+4.4 mm Hg; 95% CI: +2.5 to +6.4 mm Hg; P < 0.0001), even after adjustment for HOMA-IR (+4.7 mm Hg; 95% CI: +2.7 to +6.7 mm Hg; P < 0.0001). Greater fat mass, BMI, and waist circumference were associated with higher PCWP at rest and exercise (P < 0.0009 for all), but HOMA-IR was not (+0.01 mm Hg; 95% CI: -0.13 to +0.16 mm Hg; P = 0.84). Findings were similar evaluating diabetes in place of IR, and were replicated in the independent HFpEF cohort (n = 254), where BMI remained independently associated with higher rest and exercise PCWP (+0.19 mm Hg [95% CI: +0.11 to +0.27 mm Hg] per kg/m2; P < 0.0001), but diabetes was not. CONCLUSIONS: Excess adiposity is present in most patients with HFpEF, even among those not considered obese according to BMI, calling for further study of cardiometabolic therapies among patients with HFpEF and excess adiposity with BMI <30 kg/m2. Although excess body fat is associated with IR and diabetes, cardiac remodeling, hemodynamics, and functional impairment are independently correlated with body fat, but not IR. These findings suggest that diabetes is primarily a marker of greater adiposity in HFpEF, with less direct impact on heart failure severity. (Pulmonary Vascular Disease Phenomics Program [PVDOMICS]; NCT02980887).
引用
- Reddy YNV, Frantz RP, Hemnes AR, et al. Disentangling the Impact of Adiposity From Insulin Resistance in Heart Failure With Preserved Ejection Fraction. J Am Coll Cardiol. 2025. PMID: 40335254. doi:10.1016/j.jacc.2025.03.530
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。